- Home
- IMMP vs HCAT Comparison
IMMP vs HCAT Comparison
Compare IMMP & HCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- HCAT
- Stock Information
- Founded
- IMMP 1987
- HCAT 2008
- Country
- IMMP Australia
- HCAT United States
- Employees
- IMMP N/A
- HCAT N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- HCAT Computer Software: Programming Data Processing
- Sector
- IMMP Health Care
- HCAT Technology
- Exchange
- IMMP Nasdaq
- HCAT Nasdaq
- Market Cap
- IMMP 251.8M
- HCAT 237.9M
- IPO Year
- IMMP N/A
- HCAT 2019
- Fundamental
- Price
- IMMP $1.73
- HCAT $3.01
- Analyst Decision
- IMMP Buy
- HCAT Hold
- Analyst Count
- IMMP 1
- HCAT 11
- Target Price
- IMMP $7.00
- HCAT $4.70
- AVG Volume (30 Days)
- IMMP 87.9K
- HCAT 886.4K
- Earning Date
- IMMP 10-21-2025
- HCAT 11-05-2025
- Dividend Yield
- IMMP N/A
- HCAT N/A
- EPS Growth
- IMMP N/A
- HCAT N/A
- EPS
- IMMP N/A
- HCAT N/A
- Revenue
- IMMP $3,306,742.00
- HCAT $316,093,000.00
- Revenue This Year
- IMMP N/A
- HCAT $5.57
- Revenue Next Year
- IMMP $725.37
- HCAT $2.32
- P/E Ratio
- IMMP N/A
- HCAT N/A
- Revenue Growth
- IMMP 31.28
- HCAT 5.55
- 52 Week Low
- IMMP $1.32
- HCAT $2.52
- 52 Week High
- IMMP $2.71
- HCAT $9.24
- Technical
- Relative Strength Index (RSI)
- IMMP 54.53
- HCAT 38.86
- Support Level
- IMMP $1.60
- HCAT $3.13
- Resistance Level
- IMMP $1.68
- HCAT $3.42
- Average True Range (ATR)
- IMMP 0.06
- HCAT 0.19
- MACD
- IMMP 0.01
- HCAT -0.02
- Stochastic Oscillator
- IMMP 82.35
- HCAT 15.51
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
About HCAT Health Catalyst Inc
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.